Bio-Techne Corporation’s Price Falls Slightly Despite Positive Analysts’ Opinions
January 6, 2023
Trending News 🌧️
BIO-TECHNE ($NASDAQ:TECH): Bio-Techne Corporation is a global biotechnology company that develops and manufactures reagents, instruments, and software used in the life sciences industry. With a strong portfolio of products, Bio-Techne provides innovative solutions to the healthcare, academic, and government sectors. On Friday 12/30/22, the stock of Bio-Techne Corporation closed at $82.88, a 1.88% decrease from the previous day’s closing price. Despite the slight drop in price, analyst opinions of the company have been positive. Analysts have been encouraged by Bio-Techne’s recent acquisition of R&D Systems, Inc., which broadens the company’s product portfolio and bolsters its presence in the market. Furthermore, Bio-Techne has recently announced that it will be expanding its product line by introducing new molecular biology reagents to its portfolio.
Analysts’ opinion of Bio-Techne is largely positive due to its strong financial results and potential for growth. These positive results have led analysts to believe that Bio-Techne is well positioned to continue its growth trajectory. Despite the slight drop in price, analysts appear to be confident in Bio-Techne’s future prospects. With a strong portfolio of products and a focus on innovation, the company looks to be well positioned to capitalize on current market trends. Going forward, investors should keep an eye on future developments as they could provide insight into the company’s future performance.
Market Price
Bio-Techne Corporation‘s stock price fell slightly on Tuesday despite positive news coverage and analyst opinions. At the time of writing, the company had mostly positive news coverage, with analysts further suggesting that the company was well-positioned for continued growth in the near future. Despite this, the stock opened at $83.9 and closed at $82.5, representing a decrease of 0.4% from the previous closing price of $82.9. The drop in price was modest, though it was still noticeable, and investors were likely waiting to see if the company could meet its potential. Analysts have often cited the company’s robust research and development capabilities as a key strength, and its ability to innovate and develop new products has been described as a key factor in its success.
Additionally, the company has a strong presence in the healthcare industry, providing products used in medical diagnostics and treatments. The company remains well-positioned for continued growth in the near future, however, and investors are likely watching to see if it can meet its potential. With its strong research and development capabilities, presence in the healthcare industry, and ability to innovate and develop new products, Bio-Techne Corporation is well-positioned to benefit from future growth opportunities. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Bio-techne Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 1.12k | 291.88 | 25.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bio-techne Corporation. More…
| Operations | Investing | Financing |
| 332.92 | -109.42 | -234.97 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bio-techne Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.35k | 599.57 | 44.64 |
Key Ratios Snapshot
Some of the financial key ratios for Bio-techne Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 15.0% | 23.2% | 31.3% |
| FCF Margin | ROE | ROA |
| 25.5% | 12.6% | 9.3% |
VI Analysis
BIO-TECHNE CORPORATION is a high risk investment according to VI Risk Rating. This rating applies to both financial and business aspects, as it reflects the company’s long term potential. VI App has also detected 3 risk warnings in income sheet, balance sheet, and non-financial fields, which can give investors a better understanding of the company and help them make an informed decision. Investors should be aware of the risks associated with investing in BIO-TECHNE CORPORATION and be sure to do their due diligence before making any investments. They should also monitor the company’s financial performance, as well as its operations, to assess their investment risk. Financial data, such as income statements, balance sheets, and cash flow statements, should be analyzed in depth to evaluate the company’s performance and potential. Additionally, investors should consider the company’s competitive landscape and market conditions to ensure they are investing in a company with a sustainable and profitable future. Moreover, a comprehensive analysis of the company’s management team should be conducted to determine their experience and qualifications. As a high risk investment, investors should also be conscious of BIO-TECHNE CORPORATION’s liquidity position and capital structure to assess whether they would be able to access their funds in the event of financial turmoil. Overall, investing in BIO-TECHNE CORPORATION is a high risk decision. Investors should take into account all the relevant information before making an investment decision and consult with an experienced financial advisor if needed. Registering with VI App will give investors access to more detailed risk warnings and data that could help them make an informed decision. More…
VI Peers
In the realm of biotechnology, there is fierce competition between companies to provide the best products and services. Among these companies is Bio-Techne Corp, which competes against Proteomics International Laboratories Ltd, AEterna Zentaris Inc, AXIM Biotechnologies Inc, and others. While each company has its own strengths and weaknesses, Bio-Techne Corp has been able to distinguish itself through its innovative products and cutting-edge technology. As the biotechnology landscape continues to evolve, it will be interesting to see how these companies adapt and change in order to stay ahead of the competition.
– Proteomics International Laboratories Ltd ($ASX:PIQ)
Proteomics International Laboratories Ltd is a company that specializes in providing proteomics services. Its market cap as of 2022 was 110.87M, and its ROE was -75.41%. The company’s main services include proteomics research, biomarker discovery, and protein quantification. Proteomics International Laboratories Ltd has a strong focus on quality and customer service, and has a team of experienced scientists that are dedicated to helping their clients achieve success.
– AEterna Zentaris Inc ($TSX:AEZS)
Aeterna Zentaris is a Canadian biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutic drugs for the treatment of cancer and endocrine disorders. As of 2022, the company had a market capitalization of $25.01 million and a return on equity of -14.54%. The company’s products include the cancer drug Macrilen, which is approved for the treatment of acromegaly, and the endocrine disorder drug Zoptarelin Doxorubicin, which is in clinical development for the treatment of breast cancer.
– AXIM Biotechnologies Inc ($OTCPK:AXIM)
AXIM Biotechnologies Inc is a clinical stage pharmaceutical company focused on the development of cannabinoid-based therapeutics. The company’s products are based on proprietary technology platforms that utilize purified cannabinoids to address specific disease conditions.
The company’s market cap is 10.55M as of 2022. The company’s ROE is 223.83%.
The company’s products are based on proprietary technology platforms that utilize purified cannabinoids to address specific disease conditions. The company is focused on the development of cannabinoid-based therapeutics to treat pain, inflammation, anxiety, and other conditions.
Summary
Bio-Techne Corporation is an American biotechnology company specializing in the development of innovative therapeutics, tools and reagents for the use of medical research and clinical diagnostics. Despite strong opinions from analysts, its stock has seen a slight dip in price. Analysts suggest this could be due to the current market trends, or due to the company’s focus on short-term gains rather than long-term growth. Regardless, Bio-Techne Corporation remains a viable investment option for those looking to diversify their portfolio with a reputable company in the biotechnology sector.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
